Laures, N.; Konecki, C.; Brugel, M.; Giffard, A.-L.; Abdelli, N.; Botsen, D.; Carlier, C.; Gozalo, C.; Feliu, C.; Slimano, F.;
et al. Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis. Pharmaceutics 2022, 14, 2119.
https://doi.org/10.3390/pharmaceutics14102119
AMA Style
Laures N, Konecki C, Brugel M, Giffard A-L, Abdelli N, Botsen D, Carlier C, Gozalo C, Feliu C, Slimano F,
et al. Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis. Pharmaceutics. 2022; 14(10):2119.
https://doi.org/10.3390/pharmaceutics14102119
Chicago/Turabian Style
Laures, Nicolas, Céline Konecki, Mathias Brugel, Anne-Lise Giffard, Naceur Abdelli, Damien Botsen, Claire Carlier, Claire Gozalo, Catherine Feliu, Florian Slimano,
and et al. 2022. "Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis" Pharmaceutics 14, no. 10: 2119.
https://doi.org/10.3390/pharmaceutics14102119
APA Style
Laures, N., Konecki, C., Brugel, M., Giffard, A.-L., Abdelli, N., Botsen, D., Carlier, C., Gozalo, C., Feliu, C., Slimano, F., Djerada, Z., & Bouché, O.
(2022). Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis. Pharmaceutics, 14(10), 2119.
https://doi.org/10.3390/pharmaceutics14102119
